Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
clopidogrel, Acetylsalicylic acid
Teva Pharma B.V.
B01AC30
clopidogrel, acetylsalicylic acid
combinations
Acute Coronary Syndrome; Myocardial Infarction
Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed‑dose combination medicinal product for continuation of therapy in:Non‑ST segment elevation acute coronary syndrome (unstable angina or non‑Q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy
Revision: 1
Withdrawn
2014-09-01
59 B. PACKAGE LEAFLET Medicinal product no longer authorised 60 PACKAGE LEAFLET: INFORMATION FOR THE USER CLOPIDOGREL/ACETYLSALICYLIC ACID TEVA 75 MG/75 MG FILM-COATED TABLETS clopidogrel/acetylsalicylic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. . WHAT IS IN THIS LEAFLET 1. What Clopidogrel/Acetylsalicylic acid Teva is and what it is used for 2. What you need to know before you take Clopidogrel/Acetylsalicylic acid Teva 3. How to take Clopidogrel/Acetylsalicylic acid Teva 4. Possible side effects 5. How to store Clopidogrel/Acetylsalicylic acid Teva 6. Contents of the pack and other information 1. WHAT CLOPIDOGREL/ACETYLSALICYLIC ACID TEVA IS AND WHAT IT IS USED FOR Clopidogrel/Acetylsalicylic acid Teva contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products. Platelets are very small structures in the blood which clump together during blood clotting. By preventing this clumping in some types of blood vessels (called arteries), antiplatelet medicinal products reduce the chances of blood clots forming (a process called atherothrombosis). Clopidogrel/Acetylsalicylic acid Teva is taken by adults to prevent blood clots forming in hardened arteries which can lead to atherothrombotic events (such as stroke, heart attack, or death). You have been prescribed Clopidogrel/Acetylsalicylic acid Teva in place of the two separate medicines, clopidogrel and ASA, to help prevent blood clots because you have experienced a severe type of chest pain known as ‘unst Aqra d-dokument sħiħ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid (ASA). Excipient with known effect: Each film-coated tablet contains 102.6 mg of lactose (as lactose monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet) Yellow, film-coated capsule shaped tablets. The tablets have a length of 14.0 mm and a width of 6.8 mm. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed-dose combination medicinal product for continuation of therapy in: Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy For further information please refer to section 5.1. _ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ _ Posology Adults and elderly population Clopidogrel/Acetylsalicylic acid Teva should be given as a single daily 75 mg/75 mg dose. Clopidogrel/Acetylsalicylic acid Teva is used following initiation of therapy with clopidogrel and ASA given separately. - _In patients with non-ST segment elevation acute coronary syndrome_ (unstable angina or non-Q-wave myocardial infarction): The optimal duration of treatment has not been formally established. Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (see section 5.1). If the use of the combination of clopidogrel/acetylsalic Aqra d-dokument sħiħ